Protocolsβ€ΊSports Recovery & Performance Protocol
IntermediateSports Recovery8 weeks

Sports Recovery & Performance Protocol

Accelerate soft-tissue injury recovery, reduce systemic inflammation, and restore peak athletic performance

Patient profile: Active adults 20–55 with tendon, ligament, or muscle injuries; or athletes seeking enhanced recovery between training cycles

Want a personalised protocol?

Our AI generator builds a protocol tailored to your profile and goals.

Generate protocol β†’
⚠️

This protocol is an educational example only. It does not apply to your specific health situation. Medical supervision is required. Peptide therapy is not approved by regulatory bodies for many of the described indications.

Protocol Stack

BPC-157

Primary

Dose

250 mcg

Frequency

Twice daily SC

Timing

Morning fasted + evening

Duration

8 weeks

TB-500 (Thymosin Beta-4)

Primary

Dose

2.0 mg

Frequency

2x/week SC

Timing

Post-workout or morning

Duration

Weeks 1–6, then taper to 1x/week weeks 7–8

Ipamorelin

Optional

Dose

200 mcg

Frequency

5x/week SC

Timing

Before bed (GH pulse for overnight repair)

Duration

8 weeks

Monitoring Parameters

  • βœ“Tissue-specific pain score (VAS 0–10) β€” weekly
  • βœ“Range of motion assessment β€” weeks 0, 4, 8
  • βœ“Ultrasound imaging of injury site β€” baseline and week 8 (if available)
  • βœ“High-sensitivity CRP β€” baseline, week 4, week 8
  • βœ“Functional performance test relevant to sport
  • βœ“IGF-1 if Ipamorelin is used

Expected Outcomes

1

Week 1–2: Reduced local inflammation, pain scores begin declining

2

Week 3–4: Improved range of motion, tendon/ligament flexibility returning

3

Week 5–6: Athletes report return-to-training milestones, tissue tensile strength improving

4

Week 7–8: Full or near-full recovery in majority of acute injury cases; chronic injuries show 40–60% improvement

Contraindications

  • βœ—Active systemic infection
  • βœ—Malignancy β€” BPC-157 promotes angiogenesis which may stimulate tumor growth
  • βœ—Recent surgery less than 4 weeks prior (coordinate with surgeon)
  • βœ—Active autoimmune disease (TB-500 is an immune modulator)

Clinical Notes

BPC-157 and TB-500 have complementary mechanisms: BPC-157 primarily drives local tissue repair through nitric oxide and growth factor upregulation, while TB-500 promotes actin polymerization and systemic anti-inflammatory action. Combining both provides superior outcomes compared to monotherapy. Subcutaneous injection proximal to the injury site is preferred for BPC-157.

Case Study

Clinical Practice Example

Male runner, 38, with grade II Achilles tendinopathy unresponsive to 3 months of physiotherapy and eccentric loading. VAS pain 7/10 at baseline. BPC-157 injected 2 cm proximal to injury + systemic TB-500. At week 4: VAS 3/10, returned to easy running. At week 8: VAS 1/10, returned to full training load. Ultrasound confirmed structural tendon improvement.

← Back to all protocols